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Abstract Cancer chemotherapy treatment often leads to
hair loss, which may be prevented by cooling the scalp
during drug administration. The current hypothesis for the
hair preservative effect of scalp cooling is that cooling of
the scalp skin reduces blood flow (perfusion) and chemical
reaction rates. Reduced perfusion leads to less drugs
available for uptake, whereas the reduced temperature
decreases uptake of and damage by chemotherapy. Alto-
gether, less damage is exerted to the hair cells, and the hair
is preserved. However, the two mechanisms in the
hypothesis have not been quantified yet. To quantify the
effect of reduced drug damage caused by falling temper-
atures, we investigated the effect of local drug concentra-
tion and local tissue temperature on hair cell damage using
in vitro experiments on keratinocytes. Cells were exposed
for 4 h to a wide range of doxorubicin concentrations.
During exposure, cells were kept at different temperatures.
Cell viability was determined after 3 d using a viability test.
Control samples were used to establish a concentration–
viability curve. Results show that cell survival is signifi-
cantly higher in cooled cells (T<22° C) than in non-cooled
cells (T=37° C), but no significant differences are visible
between T=10° C and T=22° C. Based on this result and
previous work, we can conclude that there is an optimal
temperature in scalp cooling. Further cooling will only
result in unnecessary discomfort for the patient and should
therefore be avoided.
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Introduction
Chemotherapy-induced hair loss is a feared side effect of
cancer treatment (Katsimbri et al. 2000). Scalp cooling
during administration of chemotherapy prevents hair loss
(e.g., Ridderheim et al. 2003). Cooling can be achieved by
means of a cap that is pre-cooled in a freezer or that
exchanges coolant with a reservoir. The hair preservative
effect of scalp cooling is attributed both to reduced blood
flow by vasoconstriction and to reduced reaction rates in
the body at the level of the hair follicle. When the scalp is
cooled, vasoconstriction is induced, and through this, blood
flow to the hair follicle is decreased. This reduced blood
flow results in a decrease of the total amount of cytotoxic
drug available for uptake in the hair follicle. The effect of
reduced perfusion was studied by Janssen et al. (2007), and
it was found that cooling the scalp to 20° C reduces local
blood flow down to 20% of normal. A further decrease in
temperature did not result in a further decrease in local
blood flow. Based on this, it might be expected that there is
a limit in temperature below which the effectiveness of
scalp cooling will not increase anymore.
However, the hair preservative effect of scalp cooling is
also attributed to reduced cell metabolism. Because of
reduced temperatures during scalp cooling, cellular drug
uptake and damage are assumed to be lower, and with this,
hair follicles are thought to be less susceptible to cytotoxic
drugs. Decorti et al. (2003) showed that in vitro doxorubi-
cin uptake in kidney cells at 37° C was 4.5 times higher
than drug uptake at 4° C. In addition, Decorti also showed
that doxorubicin uptake is dependent on extracellular concen-
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quantify these processes in the human hair follicle.
For a better understanding of the functioning of scalp
cooling, it is important to quantify the contribution of
reduced drug uptake and drug damage, if any, on the hair
preservative effect of scalp cooling. To this end, we
investigated experimentally the relationship between doxo-
rubicin exposure and cell damage at different temperatures
using normal human epidermal keratinocytes.
Chemotherapy disrupts the rapidly dividing keratino-
cytes (the cells that actually produce the hair shaft) in the
hair follicle (Cotsarelis and Millar 2001). Therefore, the use
of keratinocytes as an in vitro model is indicative for
chemotherapy-induced damage to the hair follicle. More-
over, human keratinocytes are commercially available and
they are easy to cultivate, which means that with this
model, a wide range of boundary conditions can quickly be
investigated.
The goal of the experiments was to assess the effects of
temperature and chemotherapy on keratinocyte survival.
Materials and Methods
Pooled neonatal normal human epidermal keratinocytes
(NHEK) were obtained from Cambrex Bio Science
Verviers, Belgium (catalog number CC-2507). These cells
have a doubling time of approximately 24 h. Cells were
cultured in T-75 flasks at a seeding density of 3,500 cells
cm
2 under an atmosphere of 95% air and 5% CO2 at 37° C
using 15 ml of keratinocyte general medium (KGM2;
Cambrex Bio Science Verviers, catalog number CC-3107).
Medium was refreshed the day after plating, and afterwards
every other day until cells reached 70–80% confluence.
Then, cells were harvested using 6 ml of trypsin solution
and subsequently cryopreserved in liquid nitrogen at a
density of 1.2×10
6 cells per milliliter using 80% KGM2,
10% fetal bovine serum, and 10% dimethyl sulfoxide
(DMSO).
For the experiments on the effect of temperature and
chemotherapy on keratinocyte survival, third passage cells
were plated in 24-well plates at a cell density of 6,000 cells
per square centimeter. Cells were incubated at 37° C for a
period of 24 h to allow the cells to recover from handling.
Concentrations of doxorubicin in KGM2 (0.01, 0.04, 0.1,
0.5, 1.0, 3.0, or 10.0 μgm l
−1) were prepared. Cells were
then exposed to 250 μl of a specific doxorubicin concentra-
tion. Plates were incubated for 4 hat either a low temperature
(TL=10° C), a medium temperature (TM=22° C), or a high
temperature (TH=37° C). For each combination of temper-
ature and doxorubicin concentration, a sample size of eight
was used. Cells receiving medium without any doxorubicin
were used as a control group for each specific temperature.
At the end of the exposure time, doxorubicin was removed,
and cells were washed with 500 μl phosphate-buffered
saline (PBS). Fresh medium (250 μl per well) was added to
each well, and plates were then incubated at 37° C for a
post-exposure time of 72 h, after which, a viability assay
was performed as described below.
The damage to the NHEK cells exposed to different
temperatures and doxorubicin concentrations was deter-
mined by a colorimetric MTT (tetrazolium) viability assay.
The assay is based on the observation that viable cells have
the ability to metabolize a water-soluble tetrazolium dye 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bro-
mide (MTT) into a product termed purple formazan
(Mosmann 1983; Edmondson et al., 1988; Sgouras and
Duncan, 1990). The purple formazan can be solubilized,
and the optical density of the solute can be determined
using a spectrophotometric technique. The resulting absor-
bance is directly proportional to the number of cells, and
this linearity extends over a wide range of cell numbers
(Mosmann 1983). A standard MTT solution was prepared
by dissolving 5 mg ml
−1 of MTT (MTT formazan, Sigma
Aldrich, Zwijndrecht, The Netherlands) in PBS. The
standard MTT solution was added to complete medium
(KGM2) in a ratio of 1 to 10 to obtain a final solution of
10% MTTsolution and 90% KGM2. Avolume of 220 μlo f
this solution was added to all test wells, and the plates were
left to incubate at 37° C and 5% CO2 for a period of
45 min. After this period, the MTT/medium solution was
removed, and 200 μl of a solution of 90% DMSO and 10%
Triton X was added to extract the purple formazan salt from
the cells. Plates were sealed and kept in dark for 30 min,
after which, 100 μl of each well was transferred to a new
well of a 96-well plate. The optical density (OD) was
measured using an automated spectrophotometric plate
reader (Synergy HT, BioTek Instruments Inc., Winooski,
VT, USA) set to 570 nm and using a reference
wavelength of 650 nm. Blanks (100 μl of DMSO/Triton
X solution only) were used as an extra control. For each
well, the corrected optical density OD(570–650 nm) was
provided by the plate reader. Mean optical density and
standard error of each temperature and concentration
group [ODT,C±SE(ODT,C)] and their respective control
group [ODT,0±SE(ODT,0)] were calculated. Based on
these values, the viability (S) for each temperature and
concentration group can be calculated as:
ST;C ¼
ODT;C
ODT;C
ð1Þ
An analysis of variance (ANOVA) was performed using
statistical software (SPSS version 15.0, SPSS Inc., Chicago,
IL). The ANOVA test is used to investigate whether
significant differences in mean values exist between two
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the effect of temperature on the one hand, and the effect of
doxorubicin concentration on the other hand, is on cell
survival. Using a general linear model, the viability is
statistically modeled as:
ST;C ¼ m þ aT þ bC þ gðT   CÞþ" ð2Þ
This means that we investigated whether temperature,
concentration, and an interaction term are significantly
relevant for describing our data. Where appropriate, a post
hoc analysis was used using Tamhane’s T2 criterium (based
on unequal variances) to test for differences between
various doxorubicin concentrations and various exposure
temperatures. A significance level of p<0.05 was used in
these statistical tests.
Results
Microscopic photographs of cells at selected concentrations
are shown in Fig. 1. Here, we can see that the control groups
of all temperatures show similar cell counts. With increasing
concentration, the number of cells decreases. At 3 μgm l
−1
(C4), a clear difference is visible between the high
temperature group and both the medium and low temper-
ature group. The difference between these groups at other
concentrations is less well defined. It can be seen that there
is a difference in cell morphology between 0.04 μgm l
−1
(C2) and 0.5 μgm l
−1 (C3). Cells in the latter group, and in
groups with higher doxorubicin concentrations, show
enlarged and flattened cell shape and increased granularity.
These are characteristics of senescence or aging, which is
known to be caused by doxorubicin (Roninson 2003). The
results of the viability determination are shown in Fig. 2.
Figure 1. Microscopic photo-
graphs of cells exposed to se-
lected doxorubicin
concentrations. Photographs are
taken at a magnification of ten
times. C1=0.01 μgm l
−1,C 2 =
0.04 μgm l
−1, C3=0.5 μgm l
−1,
C4=3.0 μgm l
−1,C 5 =
10 μgm l
−1.
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doxorubicin concentration for different doxorubicin expo-
sure temperatures. In this figure, we can see that the
viability of keratinocytes as a function of doxorubicin
concentration shows a decreasing S-curve with increasing
concentrations. Viability levels are slightly above 1 for low
concentrations (0.01 μgm l
−1), and with increasing concen-
trations, viability gradually drops towards zero for high
concentrations (10 μgm l
−1). For different temperature
groups, cell viability at a specific concentration is always
lowest for the high temperature group. In the mid-section of
the concentration range (i.e., 0.1–1 μgm l
−1), the differ-
ences between the high temperature group (TH) and the two
lower temperature groups (TL and TM) are more pro-
nounced. Cell viability for these lower temperature groups
decreases more slowly than for the high temperature group,
until at a concentration of 1 μgm l
−1, a rapid drop in cell
viability is visible. The difference between the individual
temperature groups at low and high concentrations is
therefore small.
From an ANOVA analysis, we found that the effect of
doxorubicin concentration on NHEK viability was highly
significant [F(6,161)=165.213, p<0.001], as was the effect
of temperature on NHEK viability [F(6,161)=37.054, p<
0.001]. The effect size of doxorubicin (h2
p; partial eta
squared) was higher than the effect size of temperature
(h2
p=0.88 compared to h2
p=0.36).
For all temperature groups, increased doxorubicin
concentration has a significant decreasing effect on cell
viability. This effect was highly significant for the high
temperature group [F(6,49)=119.400, p<0.001], the inter-
mediate temperature group [F(6,49)=33.166, p<0.001],
and the lowest temperature group [F(6,49)=68.225, p<
0.001] Based on these results, a post hoc analysis was
performed for each temperature group to check where a
significant transition in cell viability as function of
doxorubicin concentration occurs. This transition point
may be viewed as the inflection point of the S-curve. For
the low and medium temperature group, we found a
transition point between 1.0 and 3.0 μgm l
−1. The highest
temperature group has a transition point slightly below
0.5 μgm l
−1.
The ANOVA analysis also revealed a significant
interaction between doxorubicin and temperature on cell
viability [F(6,161)=2.754, p=0.002], although the effect is
smaller than that of temperature and doxorubicin (h2
p=
0.199). This significant interaction term shows that the
effect of temperature on cell viability is not the same at the
levels of different doxorubicin concentrations. For low and
high doxorubicin concentrations, there is hardly any
influence of a lower temperature on cell survival. In the
mid-section of the graph this influence is far more
substantial.
The results of the ANOVA analysis are summarized in
Table 1. It can be seen that significant differences exist
between TL and TH for concentrations of 0.1 μgm l
−1 and
up, except for a concentration of 1 μgm l
−1. At this
concentration, the significance level is not high enough, but
still, a trend is visible (p<0.1). Between TM and TH,
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Figure 2. Cell viability as a function of doxorubicin concentration at
different temperatures. Delta: TL (10° C), filled square: TM (22° C),
and open circle: TH (37° C). Data points show the mean and standard
error of eight replicates. The results of a significance test are shown in
Table 1.
Table 1. Results of an ANOVA analysis for determining the significance between different temperature groups at a specific doxorubicin
concentration
Doxorubicin (μgm l
−1) F value p value TL vs TH TM vs TH TL vs TM
0.01 F(2,21)=0.315 0.733
0.04 F(2,21)=1.958 0.166
0.1 F(2,21)=15.187 <0.001 p<0.01 p<0.1*
0.5 F(2,21)=31.605 <0.001 p<0.001 p<0.001
1 F(2,21)=4.380 <0.05 p<0.1*
3 F(2,21)=12.908 <0.001 p<0.01 p<0.01
10 F(2,21)=22.587 <0.001 p<0.001 p<0.05 p<0.05
p Values are shown with their respective significance level. Trends (p<0.1) are marked with an asterisk. See text for more detail.
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−1
and up, except for a concentration of 1 μgm l
−1 where no
significant difference is visible. The only significant
difference between TL and TM exists at a concentration of
10 μgm l
−1, although a trend is visible at a concentration of
0.1 μgm l
−1.
Discussion
We examined the role reduced metabolism has on the hair
preservative effect of scalp cooling. For this, a controlled in
vitro experiment was conducted to assess the damage
exerted by doxorubicin on human epidermal keratinocytes
for a range of chemotherapy concentrations and exposure
temperatures. The effects of temperature and doxorubicin
on cell damage were determined from cell viability
measurements (MTT assay).
We found that increased doxorubicin concentrations have
a significant decreasing effect on keratinocyte cell viability.
Viability was close to 1 for low concentrations and close to 0
forhighconcentrations. In between, therelationshipbetween
doxorubicin concentration and cell viability shows an S-
curve. We also found that reduced temperature has a
significant increasing effect on keratinocyte cell viability.
The two cooled temperature groups (10° C and 22° C) show
a higher cell viability for each doxorubicin concentration
than the 37° C group. At the mid-range of doxorubicin
concentrations (0.04–1 μgm l
−1), the effect of reduced
temperature is more pronounced than in the extreme values
of doxorubicin concentration. This observation is con-
firmed by the fact that an interaction term of doxorubicin
concentration and exposure temperature was significant.
The increased effect of reduced temperature was significant
for doxorubicin concentrations of 0.1 μgm l
−1 and higher.
We found no significant differences between the low
(10° C) and medium (22° C) group.
Theresultsoftheexperimentareinlinewiththehypothesis
of scalp cooling. In this hypothesis, the reduced temperature
caused by scalp cooling will result in lower perfusion and a
lower cellular metabolism. With this, the supply, uptake and
damage of a chemotherapeutic agent will be diminished.
For low doxorubicin concentrations (0.01 and 0.04 μg
ml
−1), the MTT assay for each temperature group showed a
higher viability than the respective control group. Because
of the fact that each specific temperature group has its own
control group, it is unlikely that this effect is caused by a
measurement error. This means that apparently, cells are
metabolically more active when exposed to a small amount
of doxorubicin. It is possible that cells in the control group
are close to reaching confluence at the time that viability is
determined. As cells reach confluence, there is not enough
room for new cells. Therefore, the rate at which cells divide
will become lower, and hence, their metabolic activity will
decrease. Another possibility is that a small amount of
doxorubicin will stimulate cells to repair damage exerted to
the cells. Hence, it may actually result in larger cell growth
compared to a control group receiving no doxorubicin. At
this point, however, we have no indication for which
explanation may be true.
Another remarkable result is that there is no significant
difference between the medium and low temperature group.
Thus, it seems that there is a limit in effect of reduced
temperature. In a pilot study to determine optimal doxoru-
bicin exposure temperature, we found that an exposure
temperature of 26° C also showed increased cell viability
(data not shown), and this increase did not differ from other
temperature groups. During scalp cooling, a skin tempera-
ture of approximately 20° C is reached. Based on the results
of our experiment, one might expect that the limit in effect
of reduced temperature during scalp cooling may be
reached for a temperature as high as 26° C. This means
that during scalp cooling, the effect of reduced metabolism
is already at its maximum. However, care has to be taken
when the results of an in vitro experiment are generalized.
Therefore, further studies on the effect of reduced temper-
ature on cell damage are needed to exactly define this limit.
Ideally, an in vitro hair follicle model is used in these
studies. Our current study confines the boundary conditions
in doxorubicin concentration and exposure temperature that
can be used in these further studies.
Recently, it was shown that there is a limit in perfusion
during scalp cooling (Janssen et al. 2007). Cooling the
scalp to approximately 18° C resulted in a decrease in
perfusion to 20%. Further cooling did not result in any
further decrease in perfusion. The findings of the current
study indicate that there is no difference in cell survival
between 22° C and 10° C. Based on these findings, we can
conclude that there is an optimal temperature in scalp
cooling. Further cooling will only result in unnecessary
discomfort for the patient. Therefore, strong cooling during
scalp cooling should be avoided.
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